Clinical trials: Hepatitis B Infections
Hepatitis B
Drug Use Investigation for HEPSERA (Adefovir) Tablet
This post-marketing surveillance (PMS) is conducted to collect safety and efficacy data among subjects with chronic hepatitis B and hepatic cirrhosis B who is treated with adefovir tablets.
- Trial name
- NCT01863589
- Testing
- Adefovir tablets
- Volunteers
- 436 people
- Sponsor
- GlaxoSmithKline
Hepatitis B
First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV
This is an open-label study to determine the safety, tolerability and immunogenicity of ChAdOx1-HBV and MVA-HBV vaccines, with or without nivolumab, in patients with chronic HBV who are virally suppressed with oral anti-viral…
- Trial name
- NCT04778904
- Testing
- ChAdOx1-HBV, MVA-HBV, Nivolumab
- Where
- 12 sites in South Korea, Taiwan and 1 more
- Volunteers
- 55 people
- Sponsor
- Barinthus Biotherapeutics
Chronic Hepatitis B
A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection
The purpose of this study is to evaluate the safety, antiviral activity, and pharmacokinetics of ABI-H0731 in combination with entecavir (ETV) and with ETV plus pegylated-interferon alpha (Peg-IFNα) in Chinese participants with…
- Trial name
- NCT04781647
- Testing
- ABI-H0731, ETV, Peg-IFNα
- Where
- 9 sites in China
- Volunteers
- 54 people
- Sponsor
- Assembly Biosciences
Hepatitis B, Chronic
Entecavir Plus Adefovir in Lamivudine-Resistant Patients
Combination therapy with entecavir 1.0 mg plus adefovir 10 mg has superior antiviral activity compared with either entecavir monotherapy 1.0 mg or adefovir 10 mg plus lamivudine 100 mg in Chinese adults with lamivudine-resistant…
- Trial name
- NCT00986778
- Testing
- Lamivudine, Entecavir, Adefovir
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis B
A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients
Open-label, extension study to evaluate the safety and efficacy of combination therapy and its effect on sustained viral response biomarkers.
- Trial name
- NCT03780543
- Testing
- standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 92 people
- Sponsor
- Assembly Biosciences
Hepatitis B, Chronic
Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201
Compare the long-term safety of pradefovir to adefovir dipivoxyl
- Trial name
- NCT00230490
- Testing
- pradefovir mesylate, adefovir dipivoxyl
- Volunteers
- 150 people
- Sponsor
- Bausch Health Americas, Inc.
Hepatitis B, Chronic
Study of Safety and Tolerability of DCR HBVS
DCR-HBVS will be evaluated for safety and efficacy in healthy volunteers and chronic hepatitis B patients.
- Trial name
- NCT03772249
- Testing
- DCR-HBVS
- Where
- 9 sites in Australia, Hong Kong and 3 more
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Hepatitis B
Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination
This phase IV open study will evaluate the persistence of humoral antibodies against hepatitis B as well as the immune response to a challenge dose of hepatitis B vaccine in adolescents aged 12-13 years, who received three…
- Trial name
- NCT00984139
- Testing
- Engerix™-B Kinder
- Where
- 24 sites in Germany
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B
This study is a randomized, double-blind, placebo-controlled, multicenter phase 2 study to assess the efficacy and safety of AHB-137 injection in treatment-naïve participants with chronic hepatitis B.
- Trial name
- NCT07635186
- Testing
- AHB-137
- Where
- 34 sites in China
- Volunteers
- 320 people
- Sponsor
- Ausper Biopharma Co., Ltd.
Diphtheria, Pertussis
Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®
PR5I, a hexavalent pediatric combination vaccine is being developed to reduce the number of injections during the first 2 years of life while providing a complete course of immunization against infection caused by H.
- Conditions
- Diphtheria, Pertussis, Polio, Hepatitis B
- Trial name
- NCT00362427
- Testing
- Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC
- Where
- 8 sites in Canada
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chronic Hepatitis B
Composite Probiotics Stabilize Lipid Metabolism in Chronic Hepatitis B Patients:A Clinical Trial
The goal of this is to verify the clinical efficacy of compound probiotics in reducing HBV infection levels and regulating intestinal flora in patients with chronic hepatitis B.
- Trial name
- NCT06221605
- Testing
- Probiotic
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Hepatitis B
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
Patients with chronic HBV infection will receive either ARC-520 or placebo in combination with entecavir or tenofovir, and be evaluated for safety and efficacy.
- Trial name
- NCT02604199
- Testing
- ARC-520 Injection, entecavir, tenofovir
- Where
- 16 sites in China, Germany and 1 more
- Volunteers
- 58 people
- Sponsor
- Arrowhead Pharmaceuticals
Chronic Hepatitis B
A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B
To evaluate the efficacy and safety of combined/uncombined nucleoside (acid) analogues of TQA3810 tablets.
- Trial name
- NCT06566248
- Testing
- TQA3810 tablets+NUC
- Where
- 6 sites in China
- Volunteers
- 90 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HBV, Chronic HBV Infection
Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT02836249
- Testing
- TAF, TDF
- Where
- 25 sites in China
- Volunteers
- 181 people
- Sponsor
- Gilead Sciences
Pertussis, Tetanus
Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis
Primary objective: To determine the safety and immunogenicity of tetanus and diphtheria toxoids adsorbed combined with component pertussis and inactivated poliomyelitis vaccine grown on vero cells (TdcP-IPV) compared to tetanus…
- Conditions
- Pertussis, Tetanus, Diphtheria, Poliomyelitis
- Trial name
- NCT02040636
- Testing
- Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV, Hepatitis B vaccine
- Where
- Canada
- Volunteers
- 277 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B
A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.
The immune response of uraemic patients to hepatitis B vaccination is impaired compared to healthy subjects. After vaccination, anti-HBs peak antibody concentrations are reduced.
- Trial name
- NCT00291980
- Testing
- HB-AS02V vaccine, HBVAXPRO vaccine
- Where
- 28 sites in Belgium, Czechia and 1 more
- Volunteers
- 185 people
- Sponsor
- Henogen
Hepatitis B
A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.
The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous infusion of I.V.-Hepabig inj. in post-liver transplant patients
- Trial name
- NCT05686759
- Testing
- Undiluted I.V.-Hepabig inj(GC5103), Diluted I.V.-Hepabig inj(GC5103)
- Where
- 8 sites in South Korea
- Volunteers
- 105 people
- Sponsor
- GC Biopharma Corp
Chronic Hepatitis B
Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B
The purpose of the study is to investigate the safety and the antiviral activity of ascending multiple oral doses of LB80380 for 12 weeks in adults with lamivudine-refractory chronic hepatitis B infection.
- Trial name
- NCT00895596
- Testing
- LB80380
- Where
- 4 sites in China, South Korea
- Volunteers
- 65 people
- Sponsor
- LG Life Sciences
Hepatitis B Virus, HBV
Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials
The purpose of this study is to provide entecavir to participants who have completed another entecavir trial without achieving virologic response or who relapsed during postdosing follow-up.
- Trial name
- NCT01438424
- Testing
- Entecavir, Lamivudine
- Volunteers
- 1,053 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Hepatitis
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
The TARGET-HBV study engages an observational research design to conduct a comprehensive review of outcomes for patients with CHB infection.
- Conditions
- Hepatitis B, Hepatitis, Liver Diseases
- Trial name
- NCT03692897
- Testing
- All approved therapies for the treatment of Chronic Hepatitis B (CHB)
- Where
- 31 sites in United States, Canada
- Volunteers
- 1,708 people
- Sponsor
- Target PharmaSolutions, Inc.